Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
New words:
abnormal, abridge, Absent, accuracy, actuarial, Adaptive, addiction, addictive, Additionally, administered, advantage, advice, Agenda, andZocor, antibacterial, antibiotic, antiviral, array, Asia, assumption, attempting, attestation, automatically, AVELOX, avoid, Baxter, Bayer, BBB, Beecham, begun, bioequivalence, Biopharma, border, Centocor, CEO, Chamber, Chemical, chemistry, China, CIA, CIPRO, collusion, complex, confirmed, congestion, conjunction, consecutive, constructive, convert, convertible, core, COSO, counter, cream, creating, Creation, Creelman, criteria, critical, cumulative, decade, declared, deficiency, delivery, Delta, dermatological, desist, detected, detection, deteriorate, deterring, dialogue, diminish, diminished, disincentive, docket, dysfunction, Eisai, erectile, error, exploring, expressed, FIFO, finite, Framework, Frameworkissued, Fred, FREEZE, garenoxacin, GlaxoSmithKline, grace, growing, guilty, Ian, IBM, illicit, imposing, improper, inadequate, incident, incidental, incremental, indefinite, indefinitely, INEGY, infrastructure, ingredient, inInternal, integral, Integrated, integrity, intermediate, Investor, involuntary, iv, Kaposi, Kingdom, Kohan, Korea, Labor, leadership, Leder, LEVITRA, LIFO, Likewise, MA, mandatory, margin, matching, Medipha, methamphetamine, MHLW, Millennium, minimized, Ministry, monitoring, multiplied, NJ, NOL, obligor, opiate, opportunity, OraSure, ordinary, outsource, ovarian, overhead, override, overriding, Overview, personnel, pertain, Pfizer, pharmacist, Philip, physical, PLC, pled, plough, pocket, predominantly, processing, prudent, PSE, pseudoephedrine, psoriatic, published, quinolone, Rabbi, Reclassification, recruited, regular, reiterated, reliance, renewable, reorganized, repaid, repair, repairing, repurchased, reverting, robust, rollover, Rome, Sabatino, Sante, sarcoma, screening, SERP, shelf, shutdown, situation, Smith, SmithKline, source, spoilage, Squibb, statin, steroid, strain, strained, strategic, strong, study, sublicense, subordinated, subsidized, suffered, Summit, suncare, supervision, surveillance, technical, TEQUIN, Toyama, track, trademark, Transformational, Treadway, unauthorized, underlying, underwriting, unissued, unqualified, unremitted, unvested, upfront, upgrade, upper, Upsher, usage, vast, version, vision, volatile, vulnerable, VYTORIN, Watch, website, William, withholding, WTO
Removed:
Accountability, albuterol, Alpharma, andrx, arbitration, Argentina, BAIN, BANAMINE, Barceloneta, barring, Belgium, Biogen, Boehringer, CEDAX, CELESTAMINE, CELESTONE, CEPRAVIN, Circuit, claiming, CLEAR, Cleveland, cold, connecting, conspiracy, constitute, Copley, COPPERTONE, Cosmetic, decongestant, deeply, Diego, DIPROLENE, DIPROSONE, DIPROSPAN, discrimination, distributor, Donald, EULEXIN, falsely, GARAMYCIN, gene, Geneva, Genpharm, Goldline, hearing, Impax, implant, indeterminate, infringe, Ingelheim, issuing, LOTRISONE, maximize, McNeil, merit, Miami, Miller, Mylan, Novex, NUFLOR, nutritional, Occasionally, Omaha, operator, opted, otic, OTOMAX, outpatient, owner, PAC, pediatric, Pharma, plant, POLARAMINE, policy, Porcine, Portability, PRIME, promotant, PROVENTIL, QUADRIDERM, RALGRO, Ranbaxy, REBETRON, recharacterization, refusing, Reproductive, responding, restrain, retailer, retain, reversal, royalty, San, Singapore, SOLARCAINE, SOLEIL, solution, Spain, stating, submission, submitted, sued, sulfate, supplied, syrup, Taro, Technology, Tennessee, Teva, thereof, USA, USPD, vaccine, VALISONE, verdict, Vetmedica, vicinity, violated, violation, Wyeth, Zenith
Filing tables
Filing exhibits
- 10-K Annual report
- 10 EX-10.E.VI: Revised Form of Employment Agreement
- 10 EX-10.E.XI: Severence Benefit Plan As Amended and Restated
- 10 EX-10.L: Retirement Benefits Equalization Plan
- 10 EX-10.N: Cash Long-term Incentive Plan
- 10 EX-10.O: Long-term Performance Share Unit Incentive Plan
- 10 EX-10.W Summary of Director Compensation
- 12 EX-12: Computation of Ratio of Earnings to Fixed Charges
- 21 EX-21: Subsidiaries
- 23 EX-23: Consent of Deloitte & Touche LLP
- 24 EX-24: Power of Attorney
- 31.1 EX-31.1: Certification
- 31.2 EX-31.2: Certification
- 32.1 EX-32.1: Certification
- 32.2 EX-32.2: Certification
Related press release
MRK similar filings
Filing view
External links